Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy.
Expert Rev Pharmacoecon Outcomes Res
; 23(9): 1041-1048, 2023.
Article
in En
| MEDLINE
| ID: mdl-37459247
ABSTRACT
BACKGROUND:
This real-world analysis evaluated drug utilization focusing on wastage and healthcare costs for treatment of patients with advanced breast cancer (aBC) hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) in Italy.METHODS:
A retrospective analysis was conducted on administrative data covering about 13.3 million health-assisted individuals. Across January/2017-June/2021, all patients with HR+/HER2-aBC were identified by ≥ 1 prescription for cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i). Cost analysis was performed and updated referring to the prices of November 2021.RESULTS:
Overall, 3,647 HR+/HER2-aBC patients were included (2,627 palbociclib treated, 729 ribociclib treated, and 291 abemaciclib treated). After 12 months of follow-up, 35% of palbociclib patients had a dose reduction (on average 8.9 wasted pills/patient), 44.7% of abemaciclib patients had a dose reduction (on average 6.7 wasted pills/patient), 22.1% of ribociclib patients had a dose reduction (no wasted pills). Therapy wastage added up to 528,716 for palbociclib-treated patients (524/patient) and 5,738 in abemaciclib-treated patients (151/patient). No wastage was attributed to ribociclib.CONCLUSIONS:
Dose reduction was associated with drug wastage in palbociclib and abemaciclib-treated patients, but not in ribociclib-treated ones. These findings might be helpful to policy decision-makers who, for healthcare strategies implementation, among several variables should consider the possible restraining of drug wastage.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Purines
/
Benzimidazoles
/
Breast Neoplasms
Type of study:
Health_economic_evaluation
/
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Expert Rev Pharmacoecon Outcomes Res
Journal subject:
FARMACOLOGIA
Year:
2023
Document type:
Article
Affiliation country:
Italy